<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dimethyl sulfoxide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dimethyl sulfoxide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dimethyl sulfoxide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11938" href="/d/html/11938.html" rel="external">see "Dimethyl sulfoxide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="97034" href="/d/html/97034.html" rel="external">see "Dimethyl sulfoxide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F160865"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rimso-50</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866617"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rimso-50</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F160881"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote, Extravasation;</li>
<li>
                        Urinary Tract Product</li></ul></div>
<div class="block doa drugH1Div" id="F160867"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1436790-f5af-43d5-8b15-c07cd41c0a01">Extravasation management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management (anthracyclines, mitomycin, or mitoxantrone; off-label use):</b> Topical dimethyl sulfoxide: Apply to a region covering twice the affected area every 8 hours for 7 days. Begin within 10 minutes of extravasation; do not cover with a dressing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fef1f7c-57c6-4226-b257-b8b6de839621">Interstitial cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial cystitis:</b> Bladder instillation: Instill 50 mL directly into bladder and retain for 15 minutes; repeat every 2 weeks until symptoms are relieved, then increase intervals between treatments <b>or</b> 50 mL directly into bladder and retain for 15 to 20 minutes every 1 to 2 weeks for 4 to 8 treatments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15013658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15013658'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block doe drugH1Div" id="F160868"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F20463381"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="97034" href="/d/html/97034.html" rel="external">see "Dimethyl sulfoxide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94bea7e1-3bdb-462c-ac3b-b14c840a9dfa">Extravasation management, anthracyclines or mitomycin</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management, anthracyclines or mitomycin:</b> Limited data available: Children and Adolescents: Topical dimethyl sulfoxide: Apply to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F160853"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Body odor (garlic; duration: Up to 72 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Halitosis/unpleasant taste (garlic; onset: Within a few minutes after instillation; duration: Up to 72 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Bladder pain, cystitis (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Localized erythema (topical application; ESMO/EONS [Pérez Fidalgo 2012])</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Contact dermatitis, cystitis (eosinophilic), pigment deposits on lens</p></div>
<div class="block coi drugH1Div" id="F5683959"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F5683960"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bladder symptoms: Bladder discomfort may occur; generally diminishes with repeated administration.  </p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions have been reported with intravesical administration (rare); hypersensitivity has also occurred with topical administration. If anaphylactoid symptoms occur, manage appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic effects: Lens changes and opacities have been observed in animal studies. Full eye exams (including slit lamp) are recommended prior to use and periodically during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Taste alteration: A garlic-like taste may occur, beginning a few minutes after instillation and lasting for several hours. Garlic odor on the breath and skin may also occur and persist for up to 3 days. </p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract malignancy: Use with caution in patients with urinary tract malignancy; may be harmful due to vasodilatory effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For bladder instillation or topical administration for extravasation management (off-label use) only; not for IV or IM administration. Do not use in patients receiving dexrazoxane for anthracycline extravasation (Mourdisen, 2007); dimethyl sulfoxide (DMSO) may diminish dexrazoxane efficacy.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53914826"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Severe pain following topical administration of dimethyl sulfoxide (DMSO) has been reported in a 4-year-old patient who was receiving DMSO for idarubicin extravasation; administration of analgesia (nonopioid or opioid) prior to DMSO application did not provide effective pain control; DMSO treatment was discontinued after 5 days due to pain with application and significant erythema; after discontinuation, no further analgesia was required (Llinares 2005).</p></div>
<div class="block foc drugH1Div" id="F160858"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravesical: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rimso-50: 50% (50 mL)</p></div>
<div class="block geq drugH1Div" id="F160849"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F160862"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Rimso-50 Intravesical)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50% (per mL): $15.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866618"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravesical: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rimso-50: 50% (50 mL)</p></div>
<div class="block adm drugH1Div" id="F160860"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Intravesical (for interstitial cystitis): Instill directly into the bladder via catheter or syringe. To reduce bladder spasm, apply an analgesic lubricant (eg, lidocaine jelly) to urethra prior to catheter insertion; oral analgesics or belladonna and opium suppositories prior to administration may be of benefit. <b>Not for IV or IM use.</b></p>
<p style="text-indent:-2em;margin-left:2em;">Extravasation management (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dimethyl sulfoxide topically (within 10 minutes of extravasation) to extravasation site, covering an area twice the size of extravasation; allow to air dry; do not cover with a dressing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612580"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Not for IV or IM use.</b></p>
<p style="text-indent:-2em;margin-left:2em;">Topical: Extravasation management, anthracyclines or mitomycin: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Apply dimethyl sulfoxide <b>topically</b> (within 10 minutes of extravasation) to extravasation site, covering an area twice the size of extravasation; allow to air dry; do not cover with a dressing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F160859"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial cystitis:</b> Symptomatic relief of interstitial cystitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitation of use: There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial urinary tract infections.</p></div>
<div class="block off-label drugH1Div" id="F25475019"><span class="drugH1">Use: Off-Label: Adult</span><p>Extravasation management</p></div>
<div class="block mst drugH1Div" id="F16562878"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dimethyl sulfoxide may be confused with dimethyl fumarate</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299206"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F160854"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dexrazoxane: Dimethyl Sulfoxide may diminish the therapeutic effect of Dexrazoxane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulindac: Dimethyl Sulfoxide may enhance the neurotoxic effect of Sulindac. Dimethyl Sulfoxide may decrease the metabolism of Sulindac. Specifically, the concentrations of the active sulfide metabolite are decreased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13841189"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F20463380"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if dimethyl sulfoxide is excreted in breast milk. The manufacturer recommends that caution be exercised when administering dimethyl sulfoxide to nursing women.</p></div>
<div class="block mop drugH1Div" id="F5683993"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC, chemistry panel, liver and renal function tests about every 6 months; eye examinations and slit lamp examinations (baseline and periodically during treatment). For extravasation management, monitor and document extravasation site. </p></div>
<div class="block pha drugH1Div" id="F5683985"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">For management of cystitis, dimethyl sulfoxide (DMSO) has anti-inflammatory, analgesic, mast cell inhibition, and muscle relaxing effects (Chancellor, 2004). DMSO also has free-radical scavenger properties, which increases removal of vesicant drugs from tissues to minimize tissue damage in extravasation management (ESMO/EONS [Pérez Fidalgo 2012]).</p></div>
<div class="block phk drugH1Div" id="F5683987"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Topical: Well absorbed from application site  </p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Topical: Rapidly penetrates tissues (Bertelli 1995) </p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Oxidation to dimethyl sulfone; reduction to dimethyl sulfide</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces (as unchanged drug and dimethyl sulfone); some elimination via skin and lungs (dimethyl sulfide)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10864222">
<a name="10864222"></a>Albanell J and Baselga J, “Systemic Therapy Emergencies,” <i>Semin Oncol</i>, 2000, 27(3):347-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/10864222/pubmed" id="10864222" target="_blank">10864222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7646823">
<a name="7646823"></a>Bertelli G. Prevention and management of extravasation of cytotoxic drugs. <i>Drug Saf</i>. 1995;12(4):245-255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/7646823/pubmed" id="7646823" target="_blank">7646823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15013658">
<a name="15013658"></a>Chancellor MB and Yoshimura N, “Treatment of Interstitial Cystitis,” <i>Urology</i>, 2004, 63(Suppl 1):85-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/15013658/pubmed" id="15013658" target="_blank">15013658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151940">
<a name="15151940"></a>Ener RA, Meglathery SB, and Styler M, "Extravasation of Systemic Hemato-oncological Therapies," <i>Ann Oncol</i>, 2004, 15(6):858-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/15151940/pubmed" id="15151940" target="_blank">15151940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15770831">
<a name="15770831"></a>Llinares ME, Bermúdez M, Fuster JL, Diaz MS, Gonzalez CM. Toxicity to topical dimethyl sulfoxide in a pediatric patient with anthracycline extravasation. <i>Pediatr Hematol Oncol</i>. 2005;22(1):49-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/15770831/pubmed" id="15770831" target="_blank">15770831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10532013">
<a name="10532013"></a>Montgomery LA, Hanrahan K, Kottman K, et al, “Guideline for I.V. Infiltrations in Pediatric Patients,” <i>Pediatr Nurs</i>, 1999, 25(2):167-9, 173-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/10532013/pubmed" id="10532013" target="_blank">10532013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17185744">
<a name="17185744"></a>Mouridsen HT, Langer SW, Buter J, et al, “Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies,” <i>Ann Oncol</i>, 2007, 18(3):546-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/17185744/pubmed" id="17185744" target="_blank">17185744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Rimso-50 (dimethyl sulfoxide) [prescribing information]. Rockford, IL: Mylan Institutional LLC; July 2012.</div>
</li>
<li>
<div class="reference">
                  Rimso-50 (dimethyl sulfoxide) [prescribing information]. Rockford, IL: Mylan Institutional; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21255716">
<a name="21255716"></a>Schulmeister L. Extravasation management: clinical update. <i>Semin Oncol Nurs</i>. 2011;27(1):82-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimethyl-sulfoxide-drug-information/abstract-text/21255716/pubmed" id="21255716" target="_blank">21255716</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8898 Version 131.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
